Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report)'s stock price traded down 6.3% during mid-day trading on Friday . The company traded as low as $14.47 and last traded at $14.41. 35,897 shares were traded during mid-day trading, a decline of 78% from the average session volume of 165,247 shares. The stock had previously closed at $15.38.
Wall Street Analyst Weigh In
Several brokerages have recently weighed in on RAPP. Citizens Jmp assumed coverage on Rapport Therapeutics in a research note on Tuesday, April 8th. They set a "mkt outperform" rating for the company. JMP Securities restated a "market outperform" rating and set a $28.00 price objective on shares of Rapport Therapeutics in a research report on Tuesday, July 8th.
Read Our Latest Report on RAPP
Rapport Therapeutics Price Performance
The firm has a market cap of $534.00 million and a PE ratio of -4.24. The business's 50 day moving average price is $11.32 and its 200 day moving average price is $12.00.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.09. As a group, analysts predict that Rapport Therapeutics, Inc. will post -3.65 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS purchased a new stake in Rapport Therapeutics in the 4th quarter valued at $34,000. Deutsche Bank AG purchased a new stake in Rapport Therapeutics in the 4th quarter valued at $41,000. Virtus ETF Advisers LLC purchased a new stake in Rapport Therapeutics in the 4th quarter valued at $66,000. Wells Fargo & Company MN grew its holdings in Rapport Therapeutics by 38.9% in the 4th quarter. Wells Fargo & Company MN now owns 4,824 shares of the company's stock valued at $86,000 after buying an additional 1,352 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Rapport Therapeutics by 77.8% during the 4th quarter. JPMorgan Chase & Co. now owns 7,170 shares of the company's stock worth $127,000 after purchasing an additional 3,137 shares during the period.
Rapport Therapeutics Company Profile
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Stories
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
